{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:54:27Z","timestamp":1788173667540,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,31]]},"DOI":"10.7759\/cureus.53309","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T17:01:31Z","timestamp":1706720491000},"source":"Crossref","is-referenced-by-count":4,"title":["Botulinum Toxin for the Management of Parkinson\u2019s Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ethan","family":"Slouha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelin","family":"Mursuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atbeen","family":"Rezazadah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A","family":"Clunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theofanis F","family":"Kollias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Parkinson\u2019s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis","volume":"40","author":"DeMaagd G","year":"2015","unstructured":"DeMaagd G, Philip A. Parkinson\u2019s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharm Ther. 2015, 40:504-532.","journal-title":"Pharm Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1","article-title":"Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogeneis","author":"Kouli A","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan W. Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogeneis. Disease, Parkinson\u2019s and Pathogenesis and TB, Clinical Aspects Stoker and G.J.. Stoker TB, Greenland JC (ed): Codon Publications, Brisbane; 2018. 10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"ref3","article-title":"Parkinson Disease","author":"Zafar S","year":"2023","unstructured":"Zafar S, Yaddanapudi SS. Parkinson Disease. StatPearls, Treasure Island; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-223380","article-title":"Early-onset Parkinson\u2019s disease: creating the right environment for a genetic disorder","volume":"12","author":"Kolicheski A","year":"2022","unstructured":"Kolicheski A, Turcano P, Tamvaka N, McLean PJ, Springer W, Savica R, Ross OA. Early-onset Parkinson\u2019s disease: creating the right environment for a genetic disorder. J Parkinsons Dis. 2022, 12:2353-2367. 10.3233\/JPD-223380","journal-title":"J Parkinsons Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam PK","year":"2010","unstructured":"Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010, 55:8-14. 10.4103\/0019-5154.60343","journal-title":"Indian J Dermatol"},{"key":"ref6","article-title":"Botulinum Toxin","author":"Padda IS","year":"2023","unstructured":"Padda IS, Tadi P. Botulinum Toxin. StatPearls, Treasure Island; 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339:b2700. 10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178670","article-title":"Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections","volume":"12","author":"Samotus O","year":"2017","unstructured":"Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One. 2017, 12:e0178670. 10.1371\/journal.pone.0178670","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.06.010","article-title":"Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach","volume":"92","author":"Mittal SO","year":"2017","unstructured":"Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach. Mayo Clin Proc. 2017, 92:1359-1367. 10.1016\/j.mayocp.2017.06.010","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7916\/D8BP0270","article-title":"Effective management of upper limb Parkinsonian tremor by incobotulinumtoxinA injections using sensor-based biomechanical patterns","volume":"5","author":"Rahimi F","year":"2015","unstructured":"Rahimi F, Samotus O, Lee J, Jog M. Effective management of upper limb Parkinsonian tremor by incobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor Other Hyperkinet Mov (N Y). 2015, 5:348. 10.7916\/D8BP0270","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-2094","article-title":"Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation: a case series and a pilot study","volume":"48","author":"Gupta AD","year":"2016","unstructured":"Gupta AD, Visvanathan R. Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation: a case series and a pilot study. J Rehabil Med. 2016, 48:559-562. 10.2340\/16501977-2094","journal-title":"J Rehabil Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.42","article-title":"Effects of onabotulinum toxin A on gait in Parkinson\u2019s disease patients with foot dystonia","volume":"49","author":"Huang P","year":"2022","unstructured":"Huang P, Li YY, Park JE, et al.. Effects of onabotulinum toxin A on gait in Parkinson\u2019s disease patients with foot dystonia. Can J Neurol Sci. 2022, 49:123-128. 10.1017\/cjn.2021.42","journal-title":"Can J Neurol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7916\/D8GB24C5","article-title":"Occurrence of dysphagia following botulinum toxin injection in parkinsonism-related cervical dystonia: a retrospective study","volume":"6","author":"Patterson A","year":"2016","unstructured":"Patterson A, Almeida L, Hess CW, et al.. Occurrence of dysphagia following botulinum toxin injection in parkinsonism-related cervical dystonia: a retrospective study. Tremor Other Hyperkinet Mov (N Y). 2016, 6:379. 10.7916\/D8GB24C5","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.11.003","article-title":"Botulinum toxin for Pisa syndrome: an MRI-, ultrasound- and electromyography-guided pilot study","volume":"62","author":"Artusi CA","year":"2019","unstructured":"Artusi CA, Bortolani S, Merola A, et al.. Botulinum toxin for Pisa syndrome: an MRI-, ultrasound- and electromyography-guided pilot study. Parkinsonism Relat Disord. 2019, 62:231-235. 10.1016\/j.parkreldis.2018.11.003","journal-title":"Parkinsonism Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21694","article-title":"Botulinum toxin treatment of lateral axial dystonia in Parkinsonism","volume":"22","author":"Bonanni L","year":"2007","unstructured":"Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007, 22:2097-2103. 10.1002\/mds.21694","journal-title":"Mov Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15090566","article-title":"Longitudinal assessment of botulinum toxin treatment for lateral trunk flexion and Pisa syndrome in Parkinson\u2019s disease: real-life, long-term study","volume":"15","author":"Ledda C","year":"2023","unstructured":"Ledda C, Panero E, Dimanico U, et al.. Longitudinal assessment of botulinum toxin treatment for lateral trunk flexion and Pisa syndrome in Parkinson\u2019s disease: real-life, long-term study. Toxins (Basel). 2023, 15:566. 10.3390\/toxins15090566","journal-title":"Toxins (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2016.279","article-title":"Botulinum toxin use in refractory pain and other symptoms in Parkinsonism","volume":"43","author":"Bruno VA","year":"2016","unstructured":"Bruno VA, Fox SH, Mancini D, Miyasaki JM. Botulinum toxin use in refractory pain and other symptoms in Parkinsonism. Can J Neurol Sci. 2016, 43:697-702. 10.1017\/cjn.2016.279","journal-title":"Can J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.07.015","article-title":"Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study","volume":"20","author":"Tassorelli C","year":"2014","unstructured":"Tassorelli C, De Icco R, Alfonsi E, et al.. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014, 20:1140-1144. 10.1016\/j.parkreldis.2014.07.015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0108-x","article-title":"Injection of onabotulinum toxin A into the bilateral external oblique muscle attenuated camptocormia: a prospective open-label study in six patients with Parkinson\u2019s disease","volume":"7","author":"Todo H","year":"2018","unstructured":"Todo H, Yamasaki H, Ogawa G, Nishida K, Futamura N, Funakawa I. Injection of onabotulinum toxin A into the bilateral external oblique muscle attenuated camptocormia: a prospective open-label study in six patients with Parkinson\u2019s disease. Neurol Ther. 2018, 7:365-371. 10.1007\/s40120-018-0108-x","journal-title":"Neurol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12411","article-title":"Outcome on balance and gait following botulinum toxin treatment for striatal foot in Parkinson\u2019s disease","volume":"4","author":"Lindholm B","year":"2017","unstructured":"Lindholm B, Beckman A, Duzynski W, Hansson EE. Outcome on balance and gait following botulinum toxin treatment for striatal foot in Parkinson\u2019s disease. Mov Disord Clin Pract. 2017, 4:309-315. 10.1002\/mdc3.12411","journal-title":"Mov Disord Clin Pract"},{"key":"ref21","article-title":"A pilot study of the botulinum toxin injection in the psoas major muscles for freezing of gait in Parkinson\u2019s disease patients","volume":"2","author":"Neshige R","year":"2022","unstructured":"Neshige R. A pilot study of the botulinum toxin injection in the psoas major muscles for freezing of gait in Parkinson\u2019s disease patients. Neruol Curr Res. 2022, 2:1016.","journal-title":"Neruol Curr Res"},{"key":"ref22","article-title":"Botulinum toxin type B for gait freezing in Parkinson's disease","volume":"10","author":"Fernandez HH","year":"2004","unstructured":"Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson's disease. Med Sci Monit. 2004, 10:CR282-CR284.","journal-title":"Med Sci Monit"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21396","article-title":"The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study","volume":"22","author":"Gurevich T","year":"2007","unstructured":"Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study. Mov Disord. 2007, 22:880-883. 10.1002\/mds.21396","journal-title":"Mov Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000172930.63669.c8","article-title":"Botulinum toxin injections do not improve freezing of gait in Parkinson disease","volume":"65","author":"Wieler M","year":"2005","unstructured":"Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology. 2005, 65:626-628. 10.1212\/01.wnl.0000172930.63669.c8","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2017.245","article-title":"Botulinum toxin type A for pain in advanced Parkinson\u2019s disease","volume":"45","author":"Bruno V","year":"2018","unstructured":"Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH. Botulinum toxin type A for pain in advanced Parkinson\u2019s disease. Can J Neurol Sci. 2018, 45:23-29. 10.1017\/cjn.2017.245","journal-title":"Can J Neurol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.10.009","article-title":"Incobotulinum toxin A in Parkinson's disease with foot dystonia: a\u00a0double blind randomized trial","volume":"46","author":"Rieu I","year":"2018","unstructured":"Rieu I, Degos B, Castelnovo G, et al.. Incobotulinum toxin A in Parkinson's disease with foot dystonia: a\u00a0double blind randomized trial. Parkinsonism Relat Disord. 2018, 46:9-15. 10.1016\/j.parkreldis.2017.10.009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3279-4","article-title":"Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A","volume":"39","author":"Tiigim\u00e4e-Saar J","year":"2018","unstructured":"Tiigim\u00e4e-Saar J, Tamme T, Rosenthal M, Kadastik-Eerme L, Taba P. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A. Neurol Sci. 2018, 39:871-877. 10.1007\/s10072-018-3279-4","journal-title":"Neurol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease","volume":"26","author":"Guidubaldi A","year":"2011","unstructured":"Guidubaldi A, Fasano A, Ialongo T, et al.. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011, 26:313-319. 10.1002\/mds.23473","journal-title":"Mov Disord"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-014-1950-y","article-title":"The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders","volume":"36","author":"G\u00f3mez-Caravaca MT","year":"2015","unstructured":"G\u00f3mez-Caravaca MT, C\u00e1ceres-Redondo MT, Huertas-Fern\u00e1ndez I, Vargas-Gonz\u00e1lez L, Carrillo F, Carballo M, Mir P. The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. Neurol Sci. 2015, 36:275-279. 10.1007\/s10072-014-1950-y","journal-title":"Neurol Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"21","author":"Lagalla G","year":"2006","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006, 21:704-707. 10.1002\/mds.20793","journal-title":"Mov Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10420","article-title":"Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism","volume":"18","author":"Mancini F","year":"2003","unstructured":"Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003, 18:685-688. 10.1002\/mds.10420","journal-title":"Mov Disord"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.11.015","article-title":"Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?","volume":"253","author":"N\u00f3brega AC","year":"2007","unstructured":"N\u00f3brega AC, Rodrigues B, Torres AC, Enzo A, Melo A. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?. J Neurol Sci. 2007, 253:85-87. 10.1016\/j.jns.2006.11.015","journal-title":"J Neurol Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5152\/npa.2015.7477","article-title":"Effects of repeated botulinum toxin treatment for sialorrhea in patients with Parkinson\u2019s disease","volume":"52","author":"\u015een A","year":"2015","unstructured":"\u015een A, Arpaci B. Effects of repeated botulinum toxin treatment for sialorrhea in patients with Parkinson\u2019s disease. Noro Psikiyatr Ars. 2015, 52:69-72. 10.5152\/npa.2015.7477","journal-title":"Noro Psikiyatr Ars"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2298\/vsp0901009s","article-title":"Botulinum toxin in the treatment of sialorrhea","volume":"66","author":"Svetel M","year":"2009","unstructured":"Svetel M, Vasi\u0107 M, Dragasevi\u0107 N, Pekmezovi\u0107 T, Petrovi\u0107 I, Kosti\u0107 V. Botulinum toxin in the treatment of sialorrhea. Vojnosanit Pregl. 2009, 66:9-12. 10.2298\/vsp0901009s","journal-title":"Vojnosanit Pregl"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.14744\/scie.2019.41033","article-title":"Botulinum toxin treatment for sialorrhea: evaluation in patients with idiopathic Parkinson\u2019s disease","volume":"31","author":"Alag\u00f6z AN","year":"2020","unstructured":"Alag\u00f6z AN, Demiry\u00fcrek BE. Botulinum toxin treatment for sialorrhea: evaluation in patients with idiopathic Parkinson\u2019s disease. South Clin Ist Euras. 2020, 31:140-145. 10.14744\/scie.2019.41033","journal-title":"South Clin Ist Euras"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3109\/00016357.2010.545035","article-title":"Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms","volume":"69","author":"M\u00f8ller E","year":"2011","unstructured":"M\u00f8ller E, Karlsborg M, Bardow A, Lykkeaa J, Nissen FH, Bakke M. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms. Acta Odontol Scand. 2011, 69:151-157. 10.3109\/00016357.2010.545035","journal-title":"Acta Odontol Scand"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.01.007","article-title":"Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections","volume":"13","author":"Kalf JG","year":"2007","unstructured":"Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Mulleners WM, Munneke M. Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections. Parkinsonism Relat Disord. 2007, 13:532-534. 10.1016\/j.parkreldis.2007.01.007","journal-title":"Parkinsonism Relat Disord"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial","volume":"27","author":"Chinnapongse R","year":"2012","unstructured":"Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord. 2012, 27:219-226. 10.1002\/mds.23929","journal-title":"Mov Disord"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.05.005","article-title":"Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease","volume":"13","author":"Contarino MF","year":"2007","unstructured":"Contarino MF, Pompili M, Tittoto P, et al.. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord. 2007, 13:299-303. 10.1016\/j.parkreldis.2006.05.005","journal-title":"Parkinsonism Relat Disord"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4565","article-title":"Safety and efficacy of rimabotulinumtoxinb for treatment of sialorrhea in adults: a randomized clinical trial","volume":"77","author":"Isaacson SH","year":"2020","unstructured":"Isaacson SH, Ondo W, Jackson CE, et al.. Safety and efficacy of rimabotulinumtoxinb for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol. 2020, 77:461-469. 10.1001\/jamaneurol.2019.4565","journal-title":"JAMA Neurol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0085-1","article-title":"Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling","volume":"256","author":"Lagalla G","year":"2009","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009, 256:563-567. 10.1007\/s00415-009-0085-1","journal-title":"J Neurol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000101713.81253.4c","article-title":"A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease","volume":"62","author":"Ondo WG","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004, 62:37-40. 10.1212\/01.wnl.0000101713.81253.4c","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.071","article-title":"Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder","volume":"186","author":"Giannantoni A","year":"2011","unstructured":"Giannantoni A, Conte A, Proietti S, et al.. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011, 186:960-964. 10.1016\/j.juro.2011.04.071","journal-title":"J Urol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.06.023","article-title":"Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy","volume":"182","author":"Giannantoni A","year":"2009","unstructured":"Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol. 2009, 182:1453-1457. 10.1016\/j.juro.2009.06.023","journal-title":"J Urol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23717","article-title":"Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease","volume":"37","author":"Vurture G","year":"2018","unstructured":"Vurture G, Peyronnet B, Feigin A, et al.. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease. Neurourol Urodyn. 2018, 37:2669-2677. 10.1002\/nau.23717","journal-title":"Neurourol Urodyn"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2010.06.006","article-title":"Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease","volume":"16","author":"Kulaksizoglu H","year":"2010","unstructured":"Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Parkinsonism Relat Disord. 2010, 16:531-534. 10.1016\/j.parkreldis.2010.06.006","journal-title":"Parkinsonism Relat Disord"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.09.017","article-title":"OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease","volume":"83","author":"Anderson RU","year":"2014","unstructured":"Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology. 2014, 83:22-27. 10.1016\/j.urology.2013.09.017","journal-title":"Urology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105989","article-title":"Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder","volume":"9","author":"Jiang YH","year":"2014","unstructured":"Jiang YH, Liao CH, Tang DL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS One. 2014, 9:e105989. 10.1371\/journal.pone.0105989","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/217326-botulinum-toxin-for-the-management-of-parkinsons-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:41Z","timestamp":1707509681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/217326-botulinum-toxin-for-the-management-of-parkinsons-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.53309","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}